Glenn Bauman1, Peter Martin2, Jonathan D Thiessen3, Reggie Taylor3, Madeleine Moussa4, Mena Gaed4, Irina Rachinsky3, Zahra Kassam5, Joseph Chin6, Stephen Pautler6, Ting Yim Lee7, John F Valliant8, Aaron Ward9. 1. Department of Oncology, Western University and Lawson Health Research Institute, London, Canada; Department of Medical Biophysics, Western University and Lawson Health Research Institute, London, Canada. Electronic address: glenn.bauman@lhsc.on.ca. 2. Department of Medical Biophysics, Western University and Lawson Health Research Institute, London, Canada. 3. Department of Medical Imaging, Western University and Lawson Health Research Institute, London, Canada. 4. Department of Pathology, Western University and Lawson Health Research Institute, London, Canada. 5. Department of Oncology, Western University and Lawson Health Research Institute, London, Canada; Department of Medical Imaging, Western University and Lawson Health Research Institute, London, Canada. 6. Department of Oncology, Western University and Lawson Health Research Institute, London, Canada; Division of Urology, Department of Surgery, Western University and Lawson Health Research Institute, London, Canada. 7. Department of Oncology, Western University and Lawson Health Research Institute, London, Canada; Department of Medical Biophysics, Western University and Lawson Health Research Institute, London, Canada; Department of Medical Imaging, Western University and Lawson Health Research Institute, London, Canada. 8. Department of Chemistry and Chemical Biology, McMaster University, Hamilton, Canada. 9. Department of Oncology, Western University and Lawson Health Research Institute, London, Canada; Department of Medical Biophysics, Western University and Lawson Health Research Institute, London, Canada.
Abstract
An ongoing prospective study is acquiring preoperative imaging data for men with prostate cancer (PCa) using the molecular imaging agent [18F]-DCFPyL targeted against prostate-specific membrane antigen (PSMA). To date, six men (of a planned accrual of 24) with clinically localized, biopsy-proven PCa have undergone preoperative [18F]-DCFPyL positron emission tomography (PET) imaging and multiparametric magnetic resonance imaging acquired using a hybrid PET/MRI system. Lesions identified by [18F]-DCFPyL uptake on PET/MRI were characterized in terms of maximum standardized uptake value (SUVmax) and volume using a boundary threshold of 40% SUVmax. Following surgery, all prostatectomy specimens were processed using a whole-mount technique for accurate deformable co-registration and correlation with PCa foci defined on digitized pathology images. Well-defined intraprostatic dominant lesions were identified by [18F]-DCFPyL PET/MRI (mean SUVmax 11.4±8.25; mean volume 2.2±2.4cm3) in all six men. Co-registered digitized whole-mount pathology for the first case revealed that intense [18F]-DCFPyL uptake (SUVmax 27±1.1cm3) and multiparametric MRI changes (Prostate Imaging Reporting and Data System score of 4) were highly correlated with a 0.5-cm3 dominant (largest) lesion with Gleason pattern 4 PCa in the right mid peripheral zone. A smaller focus (0.01cm3) of lower-grade PCa (Gleason pattern 3) had much lower uptake (SUV 2.7). These early prospective data show that dominant intraprostatic lesions could be identified in all six men using [18F]-DCFPyL as an imaging probe. Trial accrual will continue to quantify in terms of spatial concordance the ability of [18F]-DCFPyL to identify the location and characterize the grade of intraprostatic cancer foci in clinically localized PCa. PATIENT SUMMARY: Positron emission tomography using a novel probe called [18F]-DCFPyL directed against the prostate-specific membrane antigen protein was able to identify locations of prostate cancer in the prostate glands of men undergoing imaging before surgery. In the future, such imaging may allow better targeting of treatment to the portion of the prostate containing the most aggressive components of cancer rather than treating the whole prostate in a uniform fashion.
An ongoing prospective study is acquiring preoperative imaging data for men with prostate cancer (PCa) using the molecular imaging agent [18F]-DCFPyL targeted against prostate-specific membrane antigen (PSMA). To date, six men (of a planned accrual of 24) with clinically localized, biopsy-proven PCa have undergone preoperative [18F]-DCFPyL positron emission tomography (PET) imaging and multiparametric magnetic resonance imaging acquired using a hybrid PET/MRI system. Lesions identified by [18F]-DCFPyL uptake on PET/MRI were characterized in terms of maximum standardized uptake value (SUVmax) and volume using a boundary threshold of 40% SUVmax. Following surgery, all prostatectomy specimens were processed using a whole-mount technique for accurate deformable co-registration and correlation with PCa foci defined on digitized pathology images. Well-defined intraprostatic dominant lesions were identified by [18F]-DCFPyL PET/MRI (mean SUVmax 11.4±8.25; mean volume 2.2±2.4cm3) in all six men. Co-registered digitized whole-mount pathology for the first case revealed that intense [18F]-DCFPyL uptake (SUVmax 27±1.1cm3) and multiparametric MRI changes (Prostate Imaging Reporting and Data System score of 4) were highly correlated with a 0.5-cm3 dominant (largest) lesion with Gleason pattern 4 PCa in the right mid peripheral zone. A smaller focus (0.01cm3) of lower-grade PCa (Gleason pattern 3) had much lower uptake (SUV 2.7). These early prospective data show that dominant intraprostatic lesions could be identified in all six men using [18F]-DCFPyL as an imaging probe. Trial accrual will continue to quantify in terms of spatial concordance the ability of [18F]-DCFPyL to identify the location and characterize the grade of intraprostatic cancer foci in clinically localized PCa. PATIENT SUMMARY: Positron emission tomography using a novel probe called [18F]-DCFPyL directed against the prostate-specific membrane antigen protein was able to identify locations of prostate cancer in the prostate glands of men undergoing imaging before surgery. In the future, such imaging may allow better targeting of treatment to the portion of the prostate containing the most aggressive components of cancer rather than treating the whole prostate in a uniform fashion.
Authors: Sonia Gaur; Esther Mena; Stephanie A Harmon; Maria L Lindenberg; Stephen Adler; Anita T Ton; Joanna H Shih; Sherif Mehralivand; Maria J Merino; Bradford J Wood; Peter A Pinto; Ronnie C Mease; Martin G Pomper; Peter L Choyke; Baris Turkbey Journal: AJR Am J Roentgenol Date: 2020-07-08 Impact factor: 3.959
Authors: Etienne Rousseau; Don Wilson; Frédéric Lacroix-Poisson; Andra Krauze; Kim Chi; Martin Gleave; Michael McKenzie; Scott Tyldesley; S Larry Goldenberg; François Bénard Journal: J Nucl Med Date: 2019-04-12 Impact factor: 10.057
Authors: Laura Evangelista; Fabio Zattoni; Gianluca Cassarino; Paolo Artioli; Diego Cecchin; Fabrizio Dal Moro; Pietro Zucchetta Journal: Eur J Nucl Med Mol Imaging Date: 2020-09-08 Impact factor: 9.236
Authors: Christopher W Smith; Ryan Alfano; Douglas Hoover; Kathleen Surry; David D'Souza; Jonathan Thiessen; Irina Rachinsky; John Butler; Jose A Gomez; Mena Gaed; Madeleine Moussa; Joseph Chin; Stephen Pautler; Glenn S Bauman; Aaron D Ward Journal: Phys Imaging Radiat Oncol Date: 2021-07-30
Authors: Marcin Czarniecki; Esther Mena; Liza Lindenberg; Marek Cacko; Stephanie Harmon; Jan Philipp Radtke; Frederick Giesel; Baris Turkbey; Peter L Choyke Journal: Transl Androl Urol Date: 2018-10
Authors: Yves J L Bodar; Ben G J C Zwezerijnen; Patrick J van der Voorn; Bernard H E Jansen; Ruth S Smit; Sabrine Q Kol; Dennie Meijer; Katelijne de Bie; Maqsood Yaqub; Bert A D Windhorst; Harry N H Hendrikse; André N Vis; Daniela E Oprea-Lager Journal: Eur J Nucl Med Mol Imaging Date: 2021-11-02 Impact factor: 10.057